Unum Therapeutics Announces Closing of IPO and Concurrent Private Placement with Seattle Genetics
CAMBRIDGE, Mass. — Unum Therapeutics Inc., a clinical-stage biopharmaceutical company focused on the development of novel immunotherapy products designed to harness the power of a patient’s immune system to cure cancer, today announced the closing of its initial public offering of 5,770,000 shares of common stock at a public offering price of $12.00 per share. The gross proceeds from this offering, before deducting underwriting discounts and commissions and other offering expenses, are approximately $69.2 million. Unum Therapeutics’ common stock began trading on the Nasdaq Global Select Market under the ticker symbol “UMRX” on March 29, 2018.
Morgan Stanley and Cowen are acting as joint book-running managers for the initial public offering. SunTrust Robinson Humphrey and Wedbush PacGrow are acting as lead managersBack to News